- $231.78m
- $106.61m
Brief: Palisade Bio Inc Receives China Patent Allowance For Pali-2108
Palisade Bio Inc reports results for the quarter ended March 31 - Earnings Summary
Palisade Bio Inc expected to post a loss of 70 cents a share - Earnings Preview
Brief: Palisade Bio Completes Dosing In Phase 1A Portion Of Ongoing Phase 1A/B Study Of Pali-2108
U.S. RESEARCH ROUNDUP-Ashland, Connectone Bancorp, Neurocrine Biosciences
Palisade Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Palisade Bio Inc expected to post a loss of $1.99 a share - Earnings Preview
Brief: Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis
Brief: Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Palisade Bio Inc - Offering 2.1 Million Shares At $2.43 Per Share
U.S. RESEARCH ROUNDUP- AMN Healthcare Services, Chart Industries, Home Depot
Brief: Palisade Bio Announces First Subject Dosed In Phase 1 Clinical Study Of Pali-2108 For The Treatment Of Moderate-To-Severe Ulcerative Colitis
Palisade Bio Inc expected to post a loss of $3.35 a share - Earnings Preview
Brief: Palisade Bio Cleared By Health Canada To Commence Phase 1 Clinical Study
Brief: Palisade Bio Provides Update On Progress Toward Launch Of Phase 1 Human Clinical Study For Lead Program, Pali-2108 For The Treatment Of Ulcerative Colitis
Brief: Palisade Bio Reports Data Demonstrating Pde4b Expression In Patient Cohorts Could Be Utilized As A Potential Marker For Patient Stratification
Palisade Bio Inc reports results for the quarter ended in June - Earnings Summary
Palisade Bio Inc expected to post a loss of $2.93 a share - Earnings Preview
Brief: Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108